Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 20/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.64 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.64 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14564400 | 0.84 | SCN9A (0.73) | SCN9ACYP2C9CYP3A4CYP2D6SCN10A | |
| SCHEMBL5441780 | 0.80 | SCN9A (1.00) | SCN9ACYP2C9CYP3A4CYP2D6 | |
| SCHEMBL1400209 | 0.78 | SCN9A (0.65) | SCN9ACYP2C9CYP3A4CYP2D6SCN10A | |
| SCHEMBL14564373 | 0.78 | SCN9A (0.62) | SCN9A | |
| SCHEMBL14564390 | 0.78 | SCN9A (1.00) | SCN9ACYP2C9CYP3A4CYP2D6SCN10A | |
| SCHEMBL4496810 | 0.76 | SCN9A (1.00) | SCN9ACYP2C9CYP3A4CYP2D6SCN10A | |
| SCHEMBL4489218 | 0.75 | SCN9A (0.61) | SCN9ACYP2C9CYP3A4CYP2D6SCN10A | |
| SCHEMBL14013755 | 0.74 | SCN9A (0.61) | SCN9ACYP2C9CYP3A4CYP2D6SCN10A | |
| SCHEMBL1400166 | 0.73 | SCN9A (0.65) | SCN9ACYP2C9CYP3A4CYP2D6SCN10A | |
| SCHEMBL8119163 | 0.73 | SCN9A (0.55) | SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070060584-A1 | Biaryl substituted thiazoles, oxazoles and imidazoles as sodium channel blockers | MERCK & CO., INC. | 2007-03-15 | — | — | US | disclosed |
| US-20070060584-A1 | Biaryl substituted thiazoles, oxazoles and imidazoles as sodium channel blockers | MERCK & CO., INC. | 2007-03-15 | — | — | US | disclosed |
| US-20070060584-A1 | Biaryl substituted thiazoles, oxazoles and imidazoles as sodium channel blockers | MERCK & CO., INC. | 2007-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060584-A1 | Biaryl substituted thiazoles, oxazoles and imidazoles as sodium channel blockers | TRPV1, TRPA1, TRPV3 | SCN9A 70/4885CYP2C9 1715/4885CYP3A4 1979/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.